AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ProQR Therapeutics reported Q3 GAAP EPS of -€0.10 and revenue of €2.88M, a -25.0% YoY decline. The company had €106.9 million in cash and cash equivalents as of the end of Q3, providing a runway into mid-2027.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet